
About Parnax Lab Limited
Data last updated:
Parnax Lab Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 August 1982 and has been in existence for over 44 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L36912MH1982PLC027925. Its GSTIN is 27AAACK1457E1ZT (Maharashtra). The company holds 3 GST registrations, of which 2 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 506128 and NSE: PARNAXLAB.
The company has an authorised share capital of ₹13 Cr and a paid-up capital of ₹11.49 Cr. It was formerly known as Krishna-Deep Trade and Investment Ltd. It is led by directors including Mihir Prakash Shah (Managing Director) and Ami Mihir Shah.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Gala No. 114 Bldg. No. 8 Jogani Industrial Complex Chunabhatti, Mumbai, Maharashtra, India – 400022.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹248.54 Cr, a growth of 32.4% compared to the previous year. For the same year it recorded a net profit of ₹12.8 Cr (net margin 5.2%) and EBITDA of ₹25.88 Cr (EBITDA margin 10.4%). The net worth stands at ₹95.14 Cr (up 14.5% YoY). Total assets are valued at ₹179.22 Cr (up 16.8% YoY).
Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Naxpar Group. As per MCA filings, the company has open charges of ₹24.2 Cr and satisfied charges of ₹4.66 Cr on record. Court records list 1 case involving the company, including 1 filed by the company. The company has 150 deals on record (148 market trades, 2 funding rounds), with disclosed funding of ₹24.01 Cr; the latest was in March 2022. Its 7 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 4 smaller; the largest is Galentic Pharma India Pvt Ltd with revenue of ₹195.24 Cr. The company has 14 MSME Form 1 returns on record between 2019 and 2024, listing 283 overdue payments to 41 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website naxparlab.com.
Company details
CIN history
Parnax Lab has one previous CIN (Corporate Identification Number): L67120MH1982PLC027925. The current CIN is L36912MH1982PLC027925, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L36912MH1982PLC027925 | Current |
| L67120MH1982PLC027925 | Previous |
Contact details
Parnax Lab Limited's registered office is in Mumbai, Maharashtra. Its website is naxparlab.com. Its e-mail address is in the company report.
- Email
- Website
- Registered AddressGala No. 114 Bldg. No. 8 Jogani Industrial Complex Chunabhatti, Mumbai, Maharashtra, India – 400022
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Parnax Lab Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Parnax Lab operates one associated brand: Naxpar Group. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical, cosmetic, herbal, and nutraceutical formulations are manufactured. | naxparlab.com |
Business activity
The main business activity of Parnax Lab is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Parnax Lab Limited, buy the company report.
Financials of Parnax Lab Limited
FY 2025-26 filings availableParnax Lab Limited reported revenue of ₹248.54 Cr (up 32.4% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 249 | 188 | 189 | 168 | 163 | 90.06 | 95.31 |
| Revenue growth | +32.4% | -0.5% | +12.6% | +2.8% | +81.0% | -5.5% | - |
| EBITDA | 25.88 | 26.77 | 23.55 | 22.99 | 23.03 | 9.94 | 6.43 |
| EBITDA margin | +10.4% | +14.3% | +12.5% | +13.7% | +14.1% | +11.0% | +6.8% |
| Profit before tax | 15.90 | 15.68 | 12.06 | 12.28 | 12.26 | (0.09) | (1.97) |
| Net profit | 12.80 | 11.71 | 9.60 | 8.61 | 8.23 | (0.38) | (2.92) |
| Net profit margin | +5.2% | +6.2% | +5.1% | +5.1% | +5.1% | -0.4% | -3.1% |
| EPS (₹) | 10.27 | 10.03 | 8.37 | 7.50 | 8.40 | (0.43) | (3.43) |
| Balance sheet | |||||||
| Total assets | 179 | 153 | 153 | 117 | 118 | 91.78 | 84.37 |
| Net worth | 95.14 | 83.10 | 71.58 | 62.16 | 48.18 | 32.54 | 32.79 |
| Total debt | 82.79 | 69.53 | 80.64 | 54.72 | 69.08 | 58.90 | 51.23 |
| Cash & bank | 2.26 | 2.68 | 1.88 | 2.78 | 5.78 | 1.27 | 1.30 |
| Net working capital | 48.20 | 33.72 | 40.69 | 33.66 | 38.56 | 26.63 | 24.51 |
| Cash flow | |||||||
| Cash from operations | 8.00 | 32.30 | 15.88 | 20.91 | 8.55 | 6.31 | 8.75 |
| Cash from investing | (16.39) | (16.39) | (31.52) | (9.92) | (16.50) | (6.56) | (13.33) |
| Cash from financing | 8.18 | (15.82) | 14.82 | (14.07) | 12.13 | 0.05 | 5.03 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 69.26 | 56.80 | 69.63 | 62.94 | 62.60 | 53.38 | 49.04 | 40.22 |
| Revenue growth (YoY) | +10.6% | +6.4% | +42.0% | +56.5% | +29.5% | +6.5% | - | - |
| Other income | 0.21 | 0.15 | 1.99 | 0.97 | 0.63 | 0.18 | 0.43 | 0.19 |
| EBITDA | 6.90 | 4.30 | 4.66 | 5.71 | 8.08 | 7.44 | 6.63 | 4.28 |
| EBITDA margin | +10.0% | +7.6% | +6.7% | +9.1% | +12.9% | +13.9% | +13.5% | +10.6% |
| Depreciation | 2.33 | 2.22 | 2.04 | 1.96 | 2.10 | 1.94 | 1.83 | 1.79 |
| Interest | 1.60 | 1.64 | 1.61 | 1.47 | 1.40 | 1.22 | 1.28 | 1.23 |
| Profit before tax | 3.18 | 0.59 | 3.00 | 3.25 | 5.21 | 4.46 | 3.95 | 1.45 |
| Tax | 0.99 | 0.17 | 0.81 | 0.54 | 1.58 | 1.18 | 1.03 | 0.24 |
| Net profit | 2.19 | 0.42 | 2.19 | 2.71 | 3.63 | 3.28 | 2.92 | 1.21 |
| EPS (₹) | 1.90 | 0.37 | 1.90 | 2.37 | 3.15 | 2.85 | 2.55 | 1.06 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 6.63 | 7.02 | 7.44 | 7.47 | 7.15 | 2.37 | 7.68 |
| Revenue growth | -5.6% | -5.7% | -0.4% | +4.5% | +201.7% | -69.1% | - |
| EBITDA | (1.62) | 1.24 | 2.09 | 1.56 | 1.37 | (0.45) | 0.55 |
| EBITDA margin | -24.4% | +17.7% | +28.1% | +20.9% | +19.2% | -19.0% | +7.2% |
| Profit before tax | 0.66 | 1.87 | 2.43 | 1.61 | 0.78 | (1.25) | (0.45) |
| Net profit | 0.93 | 1.41 | 1.81 | 1.19 | 0.54 | (1.13) | (1.99) |
| Net profit margin | +14.0% | +20.1% | +24.3% | +15.9% | +7.6% | -47.7% | -25.9% |
| EPS (₹) | 0.77 | 1.21 | 1.59 | 1.05 | 0.55 | (1.33) | (2.36) |
| Balance sheet | |||||||
| Total assets | 23.45 | 22.57 | 21.18 | 20.44 | 21.95 | 16.14 | 16.90 |
| Net worth | 23.42 | 22.55 | 21.16 | 19.36 | 12.75 | 4.71 | 5.82 |
| Total debt | 0.00 | 0.00 | 0.00 | 1.07 | 9.20 | 11.41 | 11.06 |
| Cash & bank | 1.10 | 1.28 | 0.46 | 1.28 | 4.35 | 0.11 | 0.12 |
| Net working capital | 10.83 | 8.96 | 6.96 | 5.57 | 6.58 | 4.18 | 5.18 |
| Cash flow | |||||||
| Cash from operations | (0.72) | 0.28 | 0.08 | (0.28) | (0.36) | 0.47 | 2.20 |
| Cash from investing | 0.57 | (0.19) | 0.30 | 0.14 | 0.00 | 0.00 | (0.01) |
| Cash from financing | (0.03) | (0.02) | (1.21) | (2.92) | 4.59 | (0.48) | (1.55) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.53 | 2.57 | 0.25 | 2.71 | 1.70 | 1.97 | 0.84 | 0.99 |
| Revenue growth (YoY) | -68.8% | +30.5% | -70.2% | +173.7% | +10.4% | -46.2% | - | - |
| Other income | 0.20 | 0.21 | 1.76 | 0.22 | 0.20 | 0.19 | 0.19 | 0.17 |
| Total expenses | 0.86 | 1.91 | 3.27 | 1.96 | 1.20 | 1.81 | 1.12 | 0.92 |
| EBITDA | (0.33) | 0.66 | (3.02) | 0.75 | 0.50 | 0.16 | (0.28) | 0.07 |
| EBITDA margin | -62.3% | +25.7% | -1208.0% | +27.7% | +29.4% | +8.1% | -33.3% | +7.1% |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Interest | 0.00 | 0.00 | 0.01 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 |
| Profit before tax | (0.15) | 0.85 | (1.29) | 0.95 | 0.66 | 0.32 | (0.12) | 0.21 |
| Tax | 0.11 | 0.00 | (0.73) | 0.24 | 0.17 | 0.08 | (0.03) | 0.05 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 69.26 | 56.80 | 69.63 | 62.94 | 62.60 | 53.38 | 49.04 | 40.22 |
| Revenue growth (YoY) | +10.6% | +6.4% | +42.0% | +56.5% | +29.5% | +6.5% | - | - |
| Other income | 0.21 | 0.15 | 1.99 | 0.97 | 0.63 | 0.18 | 0.43 | 0.19 |
| EBITDA | 6.90 | 4.30 | 4.66 | 5.71 | 8.08 | 7.44 | 6.63 | 4.28 |
| EBITDA margin | +10.0% | +7.6% | +6.7% | +9.1% | +12.9% | +13.9% | +13.5% | +10.6% |
| Depreciation | 2.33 | 2.22 | 2.04 | 1.96 | 2.10 | 1.94 | 1.83 | 1.79 |
| Interest | 1.60 | 1.64 | 1.61 | 1.47 | 1.40 | 1.22 | 1.28 | 1.23 |
| Profit before tax | 3.18 | 0.59 | 3.00 | 3.25 | 5.21 | 4.46 | 3.95 | 1.45 |
| Tax | 0.99 | 0.17 | 0.81 | 0.54 | 1.58 | 1.18 | 1.03 | 0.24 |
| Net profit | 2.19 | 0.42 | 2.19 | 2.71 | 3.63 | 3.28 | 2.92 | 1.21 |
| EPS (₹) | 1.90 | 0.37 | 1.90 | 2.37 | 3.15 | 2.85 | 2.55 | 1.06 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 249 | 188 | 189 | 168 | 163 | 90.06 | 95.31 |
| Revenue growth | +32.4% | -0.5% | +12.6% | +2.8% | +81.0% | -5.5% | - |
| Other income | 3.78 | 1.68 | 0.82 | 0.77 | 0.33 | 0.21 | 0.66 |
| Total expenses | 223 | 161 | 165 | 145 | 140 | 80.12 | 88.88 |
| Employee cost | 0.00 | 24.43 | 23.72 | 20.05 | 17.43 | 13.68 | 14.08 |
| EBITDA | 25.88 | 26.77 | 23.55 | 22.99 | 23.03 | 9.94 | 6.43 |
| EBITDA margin | +10.4% | +14.3% | +12.5% | +13.7% | +14.1% | +11.0% | +6.8% |
| Depreciation | 8.05 | 7.38 | 6.96 | 6.53 | 5.87 | 5.16 | 4.46 |
| Interest | 5.71 | 5.39 | 5.35 | 4.95 | 5.23 | 5.08 | 4.60 |
| Profit before tax | 15.90 | 15.68 | 12.06 | 12.28 | 12.26 | (0.09) | (1.97) |
| Tax | 4.10 | 4.14 | 2.42 | 3.65 | 4.01 | 0.28 | 0.95 |
| Net profit | 12.80 | 11.71 | 9.60 | 8.61 | 8.23 | (0.38) | (2.92) |
| Net profit margin | +5.2% | +6.2% | +5.1% | +5.1% | +5.1% | -0.4% | -3.1% |
| EPS (₹) | 10.27 | 10.03 | 8.37 | 7.50 | 8.40 | (0.43) | (3.43) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.49 | 11.49 | 11.49 | 11.49 | 9.81 | 8.50 | 8.50 |
| Reserves & surplus | 83.65 | 71.61 | 60.09 | 50.67 | 36.55 | 24.04 | 24.29 |
| Shareholders' funds (net worth) | 95.14 | 83.10 | 71.58 | 62.16 | 48.18 | 32.54 | 32.79 |
| Minority interest | 0.16 | 0.14 | 0.12 | 0.11 | 0.09 | 0.08 | 0.07 |
| Secured loans | 45.58 | 28.52 | 38.85 | 22.72 | 27.48 | 21.54 | 29.65 |
| Unsecured loans | 37.21 | 41.01 | 41.79 | 32.00 | 41.60 | 37.36 | 21.58 |
| Total debt | 82.79 | 69.53 | 80.64 | 54.72 | 69.08 | 58.90 | 51.23 |
| Total liabilities | 179 | 153 | 153 | 117 | 118 | 91.78 | 84.37 |
| Assets | |||||||
| Gross block | 161 | 129 | 127 | 108 | 97.25 | 79.40 | 72.73 |
| Net block | 115 | 88.26 | 89.48 | 76.80 | 71.95 | 59.67 | 57.68 |
| Capital work in progress | 11.29 | 29.44 | 20.61 | 2.33 | 3.34 | 4.91 | 2.91 |
| Investments | 0.16 | 0.16 | 0.16 | 0.16 | 0.22 | 0.22 | 0.22 |
| Inventories | 36.22 | 25.77 | 29.93 | 21.69 | 19.93 | 10.79 | 11.15 |
| Sundry debtors | 37.81 | 30.76 | 32.56 | 27.89 | 38.08 | 16.71 | 23.08 |
| Cash & bank balances | 2.26 | 2.68 | 1.88 | 2.78 | 5.78 | 1.27 | 1.30 |
| Loans & advances | 14.39 | 5.56 | 8.94 | 4.96 | 7.24 | 10.47 | 10.08 |
| Total current assets | 90.68 | 64.77 | 73.31 | 57.32 | 71.03 | 39.24 | 45.61 |
| Total current liabilities | 42.48 | 31.05 | 32.62 | 23.66 | 32.47 | 12.61 | 21.10 |
| Net working capital | 48.20 | 33.72 | 40.69 | 33.66 | 38.56 | 26.63 | 24.51 |
| Total assets | 179 | 153 | 153 | 117 | 118 | 91.78 | 84.37 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.55 | 0.46 | 1.28 | 4.36 | 0.18 | 0.39 | (0.05) |
| Net cash from operating activities | 8.00 | 32.30 | 15.88 | 20.91 | 8.55 | 6.31 | 8.75 |
| Net cash from investing activities | (16.39) | (16.39) | (31.52) | (9.92) | (16.50) | (6.56) | (13.33) |
| Net cash from financing activities | 8.18 | (15.82) | 14.82 | (14.07) | 12.13 | 0.05 | 5.03 |
| Net change in cash | (0.21) | 0.09 | (0.82) | (3.08) | 4.18 | (0.21) | 0.44 |
| Closing cash | 2.26 | 2.68 | 1.88 | 2.78 | 5.78 | 1.27 | 1.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +32.4% | -0.5% | +12.6% | +2.8% | +81.0% | -5.5% | - |
| EBITDA growth | -3.3% | +13.7% | +2.4% | -0.2% | +131.7% | +54.6% | - |
| PBT growth | +1.3% | +30.0% | -1.8% | +0.2% | +9998.0% | +95.4% | - |
| Net income growth | +9.3% | +22.0% | +11.5% | +4.6% | +2265.8% | +87.0% | - |
| Revenue CAGR (3Y) | +14.0% | +4.8% | +28.0% | +20.7% | +14.4% | -5.1% | +0.2% |
| EBITDA CAGR (3Y) | +4.0% | +5.1% | +33.3% | +52.9% | +31.1% | +0.2% | -21.0% |
| Profitability & leverage | |||||||
| Net income margin | +4.7% | +6.2% | +5.1% | +5.2% | +5.1% | -0.4% | -3.1% |
| Return on capital employed | +13.0% | +13.8% | +12.9% | +14.7% | +16.7% | +5.7% | +3.2% |
| Return on net worth | +13.2% | +14.9% | +14.4% | +15.6% | +20.5% | -1.1% | -8.5% |
| Debt / equity | 0.85 | 0.97 | 1.01 | 1.12 | 1.59 | 1.69 | 1.36 |
| Long-term debt / equity | 0.31 | 0.36 | 0.34 | 0.33 | 0.47 | 0.57 | 0.53 |
| Interest cover | 32.04 | 27.80 | 32.25 | 30.07 | 30.48 | 106.28 | 233.50 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.71 | 1.47 | 1.61 | 1.63 | 1.85 | 1.18 | 1.42 |
| Inventory turnover | 8.02 | 6.74 | 7.31 | 8.05 | 10.61 | 8.21 | 9.72 |
| Debtors turnover | 7.25 | 5.93 | 6.24 | 5.08 | 5.95 | 4.53 | 4.51 |
| EPS (₹) | 10.25 | 10.03 | 8.37 | 7.50 | 8.40 | (0.43) | (3.43) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 82.83 | 72.35 | 62.32 | 54.11 | 47.24 | 38.26 | 38.56 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.53 | 2.57 | 0.25 | 2.71 | 1.70 | 1.97 | 0.84 | 0.99 |
| Revenue growth (YoY) | -68.8% | +30.5% | -70.2% | +173.7% | +10.4% | -46.2% | - | - |
| Other income | 0.20 | 0.21 | 1.76 | 0.22 | 0.20 | 0.19 | 0.19 | 0.17 |
| Total expenses | 0.86 | 1.91 | 3.27 | 1.96 | 1.20 | 1.81 | 1.12 | 0.92 |
| EBITDA | (0.33) | 0.66 | (3.02) | 0.75 | 0.50 | 0.16 | (0.28) | 0.07 |
| EBITDA margin | -62.3% | +25.7% | -1208.0% | +27.7% | +29.4% | +8.1% | -33.3% | +7.1% |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Interest | 0.00 | 0.00 | 0.01 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 |
| Profit before tax | (0.15) | 0.85 | (1.29) | 0.95 | 0.66 | 0.32 | (0.12) | 0.21 |
| Tax | 0.11 | 0.00 | (0.73) | 0.24 | 0.17 | 0.08 | (0.03) | 0.05 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 6.63 | 7.02 | 7.44 | 7.47 | 7.15 | 2.37 | 7.68 |
| Revenue growth | -5.6% | -5.7% | -0.4% | +4.5% | +201.7% | -69.1% | - |
| Other income | 2.37 | 0.71 | 0.54 | 0.37 | 0.16 | 0.07 | 0.42 |
| Total expenses | 8.25 | 5.78 | 5.35 | 5.91 | 5.78 | 2.82 | 7.13 |
| Employee cost | 0.00 | 0.90 | 0.74 | 0.55 | 0.52 | 0.45 | 0.51 |
| EBITDA | (1.62) | 1.24 | 2.09 | 1.56 | 1.37 | (0.45) | 0.55 |
| EBITDA margin | -24.4% | +17.7% | +28.1% | +20.9% | +19.2% | -19.0% | +7.2% |
| Depreciation | 0.06 | 0.06 | 0.06 | 0.07 | 0.04 | 0.04 | 0.04 |
| Interest | 0.03 | 0.02 | 0.14 | 0.25 | 0.71 | 0.83 | 1.38 |
| Profit before tax | 0.66 | 1.87 | 2.43 | 1.61 | 0.78 | (1.25) | (0.45) |
| Tax | (0.24) | 0.46 | 0.62 | 0.42 | 0.24 | (0.12) | 1.53 |
| Net profit | 0.93 | 1.41 | 1.81 | 1.19 | 0.54 | (1.13) | (1.99) |
| Net profit margin | +14.0% | +20.1% | +24.3% | +15.9% | +7.6% | -47.7% | -25.9% |
| EPS (₹) | 0.77 | 1.21 | 1.59 | 1.05 | 0.55 | (1.33) | (2.36) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.49 | 11.49 | 11.49 | 11.49 | 9.81 | 8.50 | 8.50 |
| Reserves & surplus | 11.93 | 11.06 | 9.67 | 7.87 | 1.12 | (3.79) | (2.68) |
| Shareholders' funds (net worth) | 23.42 | 22.55 | 21.16 | 19.36 | 12.75 | 4.71 | 5.82 |
| Secured loans | 0.00 | 0.00 | 0.00 | 1.07 | 1.89 | 2.63 | 2.77 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 7.31 | 8.78 | 8.29 |
| Total debt | 0.00 | 0.00 | 0.00 | 1.07 | 9.20 | 11.41 | 11.06 |
| Total liabilities | 23.45 | 22.57 | 21.18 | 20.44 | 21.95 | 16.14 | 16.90 |
| Assets | |||||||
| Gross block | 1.08 | 1.05 | 1.05 | 0.92 | 0.87 | 0.87 | 0.87 |
| Net block | 0.39 | 0.43 | 0.49 | 0.43 | 0.44 | 0.48 | 0.53 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 10.03 | 10.03 | 10.03 | 10.03 | 10.07 | 10.07 | 10.07 |
| Inventories | 0.80 | 0.78 | 0.90 | 0.58 | 0.79 | 0.58 | 0.15 |
| Sundry debtors | 0.42 | 0.85 | 0.59 | 1.08 | 1.86 | 0.43 | 2.06 |
| Cash & bank balances | 1.10 | 1.28 | 0.46 | 1.28 | 4.35 | 0.11 | 0.12 |
| Loans & advances | 9.51 | 7.79 | 6.08 | 3.56 | 1.16 | 4.56 | 4.60 |
| Total current assets | 11.83 | 10.70 | 8.03 | 6.50 | 8.16 | 5.68 | 6.93 |
| Total current liabilities | 1.00 | 1.74 | 1.07 | 0.93 | 1.58 | 1.50 | 1.75 |
| Net working capital | 10.83 | 8.96 | 6.96 | 5.57 | 6.58 | 4.18 | 5.18 |
| Total assets | 23.45 | 22.57 | 21.18 | 20.44 | 21.95 | 16.14 | 16.90 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.50 | 0.44 | 1.27 | 4.33 | 0.10 | 0.11 | (0.53) |
| Net cash from operating activities | (0.72) | 0.28 | 0.08 | (0.28) | (0.36) | 0.47 | 2.20 |
| Net cash from investing activities | 0.57 | (0.19) | 0.30 | 0.14 | 0.00 | 0.00 | (0.01) |
| Net cash from financing activities | (0.03) | (0.02) | (1.21) | (2.92) | 4.59 | (0.48) | (1.55) |
| Net change in cash | (0.18) | 0.06 | (0.83) | (3.07) | 4.23 | (0.01) | 0.64 |
| Closing cash | 1.10 | 1.28 | 0.46 | 1.28 | 4.35 | 0.11 | 0.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -5.6% | -5.7% | -0.4% | +4.5% | +201.7% | -69.1% | - |
| EBITDA growth | -230.7% | -40.7% | +34.0% | +13.9% | +404.4% | -181.8% | - |
| PBT growth | -64.9% | -22.6% | +50.9% | +106.4% | +9998.0% | -177.8% | +13.5% |
| Net income growth | -34.0% | -22.1% | +52.1% | +120.4% | +147.8% | +43.2% | - |
| Revenue CAGR (3Y) | -3.9% | -0.6% | +46.4% | -0.9% | +3.3% | -25.8% | +13.3% |
| EBITDA CAGR (3Y) | - | -3.0% | - | +41.6% | +139.3% | -26.0% | -4.9% |
| Profitability & leverage | |||||||
| Net income margin | +13.6% | +20.2% | +24.3% | +15.9% | +7.6% | -47.7% | -25.8% |
| Return on capital employed | +2.4% | +6.7% | +9.1% | +6.2% | +6.2% | 0.0% | 0.0% |
| Return on net worth | +3.2% | +5.0% | +6.5% | +4.8% | +4.0% | 0.0% | 0.0% |
| Debt / equity | 0.00 | 0.00 | 0.03 | 0.32 | 1.18 | 2.13 | 1.63 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.04 | 0.17 | 0.44 | 0.42 |
| Interest cover | -1.79 | 1.68 | 6.90 | 16.78 | 53.38 | -169.39 | 270.59 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 6.23 | 6.69 | 7.55 | 8.35 | 8.22 | 2.72 | 8.83 |
| Inventory turnover | 8.39 | 8.36 | 10.05 | 10.91 | 10.44 | 6.49 | 26.95 |
| Debtors turnover | 10.44 | 9.75 | 8.91 | 5.08 | 6.24 | 1.90 | 3.37 |
| EPS (₹) | 0.77 | 1.21 | 1.59 | 1.05 | 0.55 | (1.33) | (2.36) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 20.39 | 19.63 | 18.42 | 16.85 | 11.14 | 5.54 | 6.85 |
To see the full year-wise statements and ratios of Parnax Lab Limited, buy the company report.
Board of directors of Parnax Lab Limited
Parnax Lab has 6 current directors and 15 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ami Mihir Shah | Director | 31 Mar 2015 | 11 Years 7 Months | Current |
| Yogesh Kantilal Varia Also directs: Naxpar Pharma Private Limited | Director | 28 May 2021 | 5 Years 5 Months | Current |
| Vijaykumar Shivaji Ayare Also directs: Wanbury Pharma Limited | Director | 10 Feb 2025 | 1 Years 9 Months | Current |
| Mihir Prakash Shah Also directs: Novomed Pharma Pvt. Ltd, Naxpar Pharma Private Limited | Managing Director | 05 Jul 2024 | 2 Years 4 Months | Current |
| Binoy Baiju Shah | Director | 05 Jul 2024 | 2 Years 4 Months | Current |
| Harish Sunderlal Panpalia Also directs: Naxpar Pharma Private Limited | Director | 11 Aug 2023 | 3 Years 3 Months | Current |
Peer comparison
Parnax Lab Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Parnax Lab Limitedthis company | ₹248.54 Cr (FY 2026) | ₹12.8 Cr | 5.2% | 32.4% | Mumbai, Maharashtra, India | |
| Galentic Pharma India Pvt Ltd | ₹195.24 Cr (FY 2025) | 56.0% | Mumbai, Maharashtra, India | |||
| Therachem Research Medilab (India) Private Limited | ₹194.12 Cr (FY 2023) | -7.0% | Jaipur, Rajasthan, India | |||
| Sriram Healthcare Private Limited | ₹192.28 Cr (FY 2025) | -8.0% | Kasauli, Himachal Pradesh, India | |||
| Regenix Drugs Limited | ₹188.37 Cr (FY 2024) | 9.0% | Chennai, Tamil Nadu, India | |||
| Goldencross Pharma Limited | ₹187.87 Cr (FY 2025) | 31.0% | Mumbai, Maharashtra, India | |||
| Comed Chemicals Limited | ₹187.35 Cr (FY 2025) | 12.0% | Vadodara, Gujarat, India | |||
| Mapra Laboratories Pvt Ltd | ₹184.45 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Parnax Lab Limited, buy the company report.
Auditor
Parnax Lab Limited is audited by M/s. C.N.Patel & Co for the financial year 2022.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| M/s. C.N.Patel & Co | FY 2022 | 112552W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 72.30%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 27.70%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 72.30% | 72.30% | 72.30% | 72.30% |
| Public | 27.70% | 27.70% | 27.70% | 27.70% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 07 Sep 2002 | 90165470 | State Bank of India | ₹10.39 Cr | Open | |
| 30 Mar 2000 | 80031525 | State Bank of India | ₹2.72 Cr | Open | |
| 30 Mar 2000 | 90350040 | State Bank of India | ₹10.39 Cr | Open | |
| 04 May 1995 | 90163159 | State Bank of India | ₹26 Lakh | Open | |
| 04 May 1995 | 90165134 | State Bank of India | ₹26 Lakh | Open |
To see the full charge records of Parnax Lab Limited, buy the company report.
Total charge records: 9 View all charges
Deals & funding
Parnax Lab Limited has 150 deals on record (148 market trades, 2 funding rounds), with disclosed funding of ₹24.01 Cr; the latest was in March 2022.
Deals on record (5 of 150)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2017 | Market trade | ₹57.8 Lakh | Buyer: Setu Securities Private Limited Seller: Setu Securities Private Limited |
| Apr 2017 | Market trade | ₹1.25 Cr | Buyer: Setu Securities Private Limited |
| Apr 2017 | Market trade | ₹61.6 Lakh | Buyer: Setu Securities Private Limited |
| Jan 2016 | Market trade | ₹39.2 Lakh | Seller: Digital Biotech Private Limited |
| Dec 2015 | Market trade | ₹98.7 Lakh | Buyer: Digital Biotech Private Limited |
To see the full deal history of Parnax Lab Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Parnax Lab Limited has 1 court case on record: 1 filed by Parnax Lab. All case is disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 1 | 0 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Writ petition | Filed by the company against Assistant Commissioner of Income Tax-7(3)(1) and 4 Ors | Disposed |
To see the full case history of Parnax Lab Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Parnax Lab Limited has 14 MSME Form 1 returns on record between 2019 and 2024, listing 283 overdue payments to 41 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 41)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Parnax Lab Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Parnax Lab has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Naxpar Pharma Private Limited | U52310MH2004PTC144449 |
To see the full group structure of Parnax Lab Limited, buy the company report.
GST
Parnax Lab has 3 GST registrations: 2 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACK1457E1ZT | Maharashtra | Active | 01 Jul 2017 |
| 26AAACK1457E2ZU | Dadra and Nagar Haveli and Daman and Diu | Active | 24 Nov 2017 |
To see the full GST registrations and return filing status of Parnax Lab Limited, buy the company report.
Recent activity
Parnax Lab Limited has 32 board changes on record since 1997: 19 appointments and 13 cessations. The latest: Tirunillai Venkateswara Anantharaman ceased to be Director on 30 Mar 2025.
40 earlier events are in the company report.
Frequently asked questions
Parnax Lab is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 03 August 1982 (44+ years old) and is registered under CIN L36912MH1982PLC027925. Listed on BSE: 506128 and NSE: PARNAXLAB.
Parnax Lab reported revenue of ₹248.54 Cr for FY 2025-26 (up 32.4% YoY) based on consolidated financials.
Parnax Lab has 6 current directors:
- Mihir Prakash Shah - Managing Director
- Ami Mihir Shah - Director
- Yogesh Kantilal Varia - Director
- Vijaykumar Shivaji Ayare - Director
- Binoy Baiju Shah - Director
- Harish Sunderlal Panpalia - Director
The latest financial statements of Parnax Lab on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Parnax Lab is 27AAACK1457E1ZT, registered in Maharashtra. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 26AAACK1457E2ZU (Dadra and Nagar Haveli and Daman and Diu).
The CIN (Corporate Identification Number) of Parnax Lab is L36912MH1982PLC027925. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Parnax Lab is a listed company as per MCA records. Its shares are listed on both BSE (code: 506128) and NSE (symbol: PARNAXLAB).
Parnax Lab has 1 court case on record: 1 filed by the company.
Parnax Lab was incorporated on 03 August 1982, making it 44+ years old. It is registered with the Registrar of Companies, Mumbai.
Parnax Lab has 150 deals on record (148 market trades, 2 funding rounds), with disclosed funding of ₹24.01 Cr; the latest was in March 2022.
The peers of Parnax Lab by revenue are Galentic Pharma India Pvt Ltd, Therachem Research Medilab (India) Private Limited, Sriram Healthcare Private Limited, Regenix Drugs Limited, Goldencross Pharma Limited and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Tirunillai Venkateswara Anantharaman ceased to be Director on 30 Mar 2025. Vijaykumar Shivaji Ayare was appointed as Director on 10 Feb 2025. Baiju Mahasukhlal Shah ceased to be Managing Director on 05 Jul 2024. Parnax Lab has 32 board changes on record in total.

